Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bill would exempt nutritional reimbursements

This article was originally published in The Tan Sheet

Executive Summary

Reps. Earl Blumenauer, D-Ore., and Ginny Brown-Waite, R-Fla., introduce July 30 the Tax Equity for Meal Replacements and Supplements Act of 2009. H.R. 3406 would exclude from employees' gross income employer-funded reimbursements of nutritional purchases with eligible health claims. In a release, Blumenauer said supplements can significantly improve health, and the measure can save money and reduce unnecessary doctor visits. The legislation follows a similar, broader bill introduced by Indiana Republican Rep. Dan Burton (1"The Tan Sheet" July 27, 2009). ... Tax advantages for infant formula: Health flexible spending arrangements could reimburse formula purchases for mothers with mastectomies who are medically unable to breastfeed, as part of H.R. 3445, introduced July 31 by Rep. Debbie Wasserman Schultz, D-Fla

You may also be interested in...

Legislation Seeks Space For Supplements On Health Care Reform Slate

Carving out a role for the dietary supplement industry in health care reform has taken on a double-edged approach. While supporting legislation focused on establishing spending on supplements as health care expenses, the industry also backs including wellness and prevention programs in health care reform plans

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

QUOTED. 17 February 2020. Ralph Ives.

The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.   





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts